In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  I like the insights gained from Bioscience Valuation's thorough assessments that allow me to support my decisions with well-founded, rational arguments.

Dr. Axel Wiest, COO R&D, Merck-Serono


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation's Publications

GREUEL, J., BODE-GREUEL, K., LOESER, T. (2020) Creating unique equity stories - Meeting the standards of US capital markets. In CAPITAL MARKET & INVESTMENT 01-2020. P.42-43

BODE-GREUEL, K. & RIMPLER, M. (2019) Einsatz künstlicher Intelligenz in der Versorgungsforschung und Kommerzialisierung. Pharm. Ind. 81(6). P.766-772

GREUEL, J. (2017) Portfolio Planning and Risk Management in the Pharmaceutical Industry 1. In THE BIOMEDICAL & LIFE SCIENCES COLLECTION. London: Henry Stewart Talks Ltd.
(Online at

GREUEL, J. (2017) Portfolio Planning and Risk Management in the Pharmaceutical Industry 2. In THE BIOMEDICAL & LIFE SCIENCES COLLECTION. London: Henry Stewart Talks Ltd.
(Online at

GREUEL, J. (2016) The Role of Modern Portfolio Management in Pharma Innovation. In SCHUHMACHER, A., HINDER, M. & GASSMANN, O. (eds.). Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. p.449-458.

NICKISCH, K. & BODE-GREUEL, K. (2016) Biosimilars Or Biobetters: Make Your Decisions Wisely. Research & analysis Journals. 2 (8). p.530-535.

BODE-GREUEL, K. & NICKISCH, K. (2014) Deciding between biobetter versus biosimilar development options based on net present value calculations. Journal of Commercial Biotechnology. 20 (2). p.21-31.

NICKISCH, K. & BODE-GREUEL, K. (2013) NPV modelling for the selection of value-creating biosimilar development candidates. Journal of Commercial Biotechnology. 19 (1). p.24-32.

SCHRÖDER-BERNHARDI, D., ENGELHARD, J., WANG, Y., BUSCH, S., BODE-GREUEL, K. (2016) Ein nationales Typ-2-Diabetes-Register. Pharm. Ind. 78(3). P.324-330

BODE-GREUEL, K. (2011) Management strategischer und operativer Risiken in der Arzneimittelentwicklung. Pharmazeutische Medizin. 13 (3). p.178-183.

BODE-GREUEL, K. & WAGNER, C. (2011) Consultants' Perspectives: Bioscience Valuation.
Focus Oncology. 3. p.13-17.

BODE-GREUEL, K. (2010) Optimierung der Risikostruktur klinischer Engtwicklungsprojekte. DGPharMed News. 12 (3). p.111-115.

BODE-GREUEL, K. & GREUEL, J. (2010) Bewertung von Biotech-Unternehmen. In DRUKARCZYK, J. & ERNST, D. (eds.). Branchenorientierte Unternehmensbewertung. 3rd Ed., Munich: Verlag Franz Vahlen. p.293-308.

BODE-GREUEL, K., GREUEL, J. and NICKISCH, K. (2009) How can pharmaceutical and biotech companies maintain a high profitability? Journal of Commercial Biotechnology. 15 (4). p.309-323.

BODE-GREUEL, K. & NICKISCH, K. (2008) Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development - Commonalities and differences in portfolio management practice. Journal of Commercial Biotechnology. 14 (4). p.307-325.

GREUEL, J. (2008) Pharma and Biotech: Is it possible to continue growing? Pharma Focus Asia. 6. p.6-9.

GREUEL, J. (2005) Assessing the economics of biogenerics. Journal of Generic Medicines. 2 (2). p.153-160.

BODE-GREUEL, K. & GREUEL, J. (2005) Determining the value of drug development candidates and technology platforms. Journal of Commercial Biotechnology. 11 (2). p.155-170.

GREUEL, J. (2002) The R&D value conundrum. Current Drug Discovery. July. p.37-42.

LOCH, C. & BODE-GREUEL, K. (2001) Evaluating growth options as sources of value for pharmaceutical research projects. R&D Management . 31 (2). p.231-248.

BODE-GREUEL, K. (2000) Real Options Evaluation in Pharmaceutical R&D: A New Approach to Financial Project Evaluation. SCRIP Reports. BS1038, 17th February. London: PJB Publications Ltd.

BODE-GREUEL, K. (1998) Making wise decisions in pharmaceutical investment. Scrip Magazine. June. p.27-28.

BODE-GREUEL, K. (1997) Financial Project Evaluation and Risk Analysis in Pharmaceutial Development. SCRIP Reports. BS890, 27th November. London: PJB Publications Ltd.

Scientific Publications - Bioscience Valuation

KLISCH, J., BODE-GREUEL, K., HORVÁTH, E., KLISCH, C. and ELS, T. (2003) Additive neuroprotective effect of Ketanserin and Ipsapirone on the hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Neurosci Lett. 15th May. 342 (1-2). p.25-28.

DE VRY, J., SCHOHE-LOOP, R., HEINE, H., GREUEL, J., MAULER, F., SCHMIDT, B. and GLASER, T. (1998) Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. Journal of Pharmacology and Experimental Therapeutics. 284 (3). p.1082-94.

SOMMERMEYER, H., SCHREIBER, R., GREUEL, J., DE VRY, J. and GLASER, T. (1993) Anxiolytic effects of the 5-HT1A receptor agonist ipsapirone in the rat: neurobiological correlates. Eur J. Pharmacol. 10th August. 240 (1). p.29-37.

SIRETEANU, R., SINGER, W., FRONIUS, M., GREUEL, J., BEST, J., FIORENTINI, A., BISTI, S., SCHIAVI, C. and CAMPOS, E. (1993) Eye alignment and cortical binocularity in strabismic kittens: a comparison between tenotomy and recession. Vis Neurosci. May-June. 0 (3). p.541-9.

KLISCH, J. & BODE-GREUEL, K. (1992) Ketanserin reduces neuronal calcium accumulation and cell death in the hippocampus of the Mongolian gerbil after transient forebrain ischemia. Brain Res. 24th April. 578 (1-2). p.1-7.

GREUEL, J., GLASER, T. (1992) The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur J Pharmacol. 11th February. 211(2). p.211-9.

BODE-GREUEL, K. & SINGER, W. (1991) Development changes of calcium currents in the visual cortex of the cat. Exp Brain Res. 84 (2). p.311-8.

BODE-GREUEL, K., KLISCH, J., HORVÁTH, E., GLASER, T. and TRABER, J. (1990) Effects of 5-hydroxytryptamine1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke. 21st December (12 Suppl). IV. p.164-6.

LUHMANN, H., GREUEL, J., SINGER, W. (1990) Horizontal Interactions in Cat Striate Cortex: II. A Current Source-Density Analysis. Eur J. Neurosci. 2 (4). p.358-368.

LUHMANN, H., GREUEL, J. and SINGER, W. (1990) Horizontal Interactions in Cat Striate Cortex: III. Ectopic Receptive Fields and Transient Exuberance of Tangential Interactions. Eur J. Neurosci. 2 (4). p.369-377.

BODE-GREUEL, K., SINGER, W. (1989) The development of N-methyl-D-aspartate receptors in cat visual cortex. Brain Res Dev Brain Res. 1st April. 46 (2). p.197-204.

GREUEL, J., LUHMANN, H. and SINGER, W. (1988) Pharmacological induction of use-dependent receptive field modifications in the visual cortex. Science. 7th October. 242 (4875). p.74-7.

BODE-GREUEL, K., SINGER, W. (1988) Developmental changes of the distribution of binding sites for organic Ca2+-channel blockers in cat visual cortex. Exp Brain Res. 70 (2). p.266-75.

GREUEL, J., LUHMANN, H. and SINGER, W. (1987) Evidence for a threshold in experience-dependent long-term changes of kitten visual cortex. Brain Res. July. 431 (1). p.141-9.

ALTMANN, L., LUHMANN,H., GREUEL, J., SINGER, W. (1987) Functional and neuronal binocularity in kittens raised with rapidly alternating monocular occlusion. J. Neurophysiol. November. 58 (5). p.965-80.

BODE-GREUEL, K., SINGER, W. and ALDENHOFF, J. (1987) A current source density analysis of field potentials evoked in slices of visual cortex. Exp Brain Res. 69 (1). p.213-9.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy